Susquehanna International Group, LLP P Lx Pharma Inc. Call Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 14, 2023	SELL	$0.15 - $0.63 $1,590 - $6,678	-10,600 Reduced 42.23%	14,500 $2,000
Q3 2022 Nov 14, 2022	SELL	$0.52 - $3.08 $12,376 - $73,304	-23,800 Reduced 48.67%	25,100 $16,000
Q2 2022 Aug 15, 2022	SELL	$1.9 - $4.18 $119,510 - $262,922	-62,900 Reduced 56.26%	48,900 $119,000
Q1 2022 May 16, 2022	BUY	$3.54 - $8.3 $85,668 - $200,860	24,200 Added 27.63%	111,800 $452,000
Q4 2021 Feb 14, 2022	SELL	$7.69 - $19.66 $1.36 Million - $3.48 Million	-176,800 Reduced 66.87%	87,600 $702,000
Q3 2021 Nov 15, 2021	BUY	$12.22 - $21.28 $2.43 Million - $4.23 Million	198,700 Added 302.44%	264,400 $5.1 Million
Q2 2021 Aug 11, 2021	BUY	$9.0 - $15.94 $591,300 - $1.05 Million	65,700 New	65,700 $907,000

62.7K

Ticker PLXP
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 29,137,700
Description
PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other asp...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.